

RESEARCH PROJECT

IP-2019-04-6211

University of Zagreb School of Dental Medicine Abstract No. 4055



Comparison of stabilization and placebo splint effect on psychological aspects and oxidative stress in chronic temporomandibular disorders

Ema Vrbanović^{1*}, Iva Z. Alajbeg^{1,5}, Ivana Lapić², Ivan Alajbeg^{3,5}, Lea Vuletić⁴

- School of Dental Medicine, University of Zagreb, Department of Removable Prosthodontics University Hospital Centre Zagreb (KBCZ), Department of laboratory Diagnostics School of Dental Medicine, University of Zagreb, Department of Oral Medicine School of Dental Medicine, University of Zagreb, Department of Physiology Department of Dentistry, University Clinical Centre Zagreb

*Presenting author:

Ema Vrbanović School of dental medicine, Univeristy of Zagreb Gundulićeva 5, 10 000 evrbanovic@sfzg.hr

OBJECTIVES

Studies imply higher psychoemotional distress in patients affected by temporomandibular disorders (TMD) when compared to controls (1,2). It has been suggested that oxidative stress (OS) plays role in experience of TMD; also, increased OS may be associated with pathogenesis of psychological disorders (3,4).

AIM: to evaluate effect of stabilization splint (SS), therapeutic modality for TMD, on psychological traits of TMD patients and compare it with placebo splint (PS), a thin thermoforming foil (Figure 2). Another aim was to assess selected OS biomarkers during TMD treatment and associate them with psychological traits.

MATERIALS AND METHODS

Thirty-four chronic TMD patients were randomized into SS and PS treatment groups and followed for 6 months (at baseline, 3rd and 6th month) (Figure 1). Outcomes included psychological aspects assessed with Graded Anxiety Disorder 7-item (GAD-7) and The Patient Health Questionnaire-9 (PHQ-9). Influence of treatment type was analyzed with regards to the levels of OS biomarkers in saliva. Selected biomarkers were Superoxide Dismutase (SOD) as antioxidant, Malondialdehyde (MDA) as oxidant and Total Antioxidant Capacity (TAC). OS markers were normalized to the concentration of total protein. Evaluation of oxidant (MDA)/antioxidant (SOD) ratio was also evaluated. Methods in detail are available in our published study (5).

Statistical analysis:

Data analyzed on an intention to treat basis, with missing data being substituted employing the K-Nearest Neighbour algorithm. A log transformation was performed for all non-normally distributed data (OS markers). Between-group analysis was performed using ANCOVA. Association between changes in treatment outcomes were tested using Pearson's correlation.

RESULTS

Participants treated with SS demonstrated greater reduction of depressive symptoms (PHQ-9 scores) after both 3rd (p=0.011, η2=0.193) and 6th month (p=0.007, n2=0.207) (Figure 3).

When compared to PS, participants in SS showed significant reduction of oxidant/antioxidant ratio (p=0.018, η 2=0.167) at 3rd month (Figure 4).

Participants treated with SS demonstrated better improvement for anxiety symptoms (GAD-7), and greater decrease in levels of TAC and MDA than participants with PS. However, the observed results were not statistically significant (p>0.05).

At 6th month the reduction of depressive symptoms (PHQ-9) was positively correlated with the decrease of afternoon TAC (r = 0.596, p = 0.007) in participants treated with SS. No significant associations were found in participants treated with

Table 1. Correlation between changes in psychological traits and TAC concentrations' change, † p<0.05.

Treatment	Reduction	3-month follow-up	6-month follow-up
		Afternoon TAC	Afternoon TAC
SS	GAD-7	0.181	0.413
	PHQ-9	-0.125	0.596 [†]
PS	GAD-7	-0.102	0.376
	PHO-9	0.151	0.216

CONCLUSION

Our data suggest that SS may effectively improve depressive symptoms in TMD patients as well as the oxidant/antioxidant ratio. Improvement of psychological aspects related to pain could be reflected in oxidative status.




Figure 1. Distribution of the participants throughout the study





Figure 2. Stabilization splint (left) and placebo splint (right) in patient's mouth




Figure 3. PHQ-9 scores changes over time in 6-month treatment period




Figure 4. MDA/SOD ratio changes over time in 6-month treatment period

LITERATURE

- 1. Carlson CR, Okeson JP, Falace DA, Nitz AJ, Curran SL, Anderson D. Comparison of psychologic and physiologic functioning between patients with masticatory muscle pain and matched controls.
- J Orofacial Pain. 215;7:15-22. 2. Fillingim RB et al. Potential psychosocial risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain. 2011;12: T46-T60.
- 3. Liu T, Zhong S, Liao X, Chen J, He T, Lai S, Jia Y. A Meta-Analysis of Oxidative Stress Markers in Depression. PLoS One.2015;10:e0138904. 4. Fedoce ADG, Ferreira F, Bota RG, Bonet-Costa V, Sun, PY, Davies KJA. The role of oxidative stress in anxiety disorder: cause or consequence? Free Radic Res. 2018;52:737-750.
- 5. Alajbeg IZ, Vrbanović E, Lapić I. et al. Effect of occlusal splint on oxidative stress markers and psychological aspects of chronic temporomandibular pain: a randomized controlled trial. Sci Rep.2020;10:10981.